# EDGAR Filing Document

**Accession Number:** 0001832332
**File Stem:** 0001193125-25-267977
**Filing Date:** 2025-11
**Character Count:** 54631
**Document Hash:** 3e8b3756db74b49819578d563e5d2243
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-267977.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001193125-25-267977

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251106

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aveanna Healthcare Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001832332
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 844717209
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0101

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40362
- **FILM NUMBER:** 251455978

**BUSINESS ADDRESS:**
- **STREET 1:** 400 INTERSTATE NORTH PARKWAY
- **STREET 2:** STE 1700
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339
- **BUSINESS PHONE:** 770-441-1580

**MAIL ADDRESS:**
- **STREET 1:** 400 INTERSTATE NORTH PARKWAY
- **STREET 2:** STE 1700
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30339

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** **November 6, 2025**

------

![img25621560_0.jpg](img25621560_0.jpg)

Aveanna Healthcare Holdings Inc.

**(Exact name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40362 | 81-4717209 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File** <br>**Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| 400 Interstate North Parkway SE**,** Atlanta**,** Georgia <br>**(Address of Principal Executive Offices)** | 30339<br>(**Zip Code)** |

---

 **(**770**)-**441-1580

**(Registrant's Telephone Number, Including Area Code)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | AVAH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On November 6, 2025, Aveanna Healthcare Holdings Inc., a Delaware corporation ("we," "us," "our" or the "Company"), issued a press release announcing its financial results for the three and nine-month periods ended September 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.

**Item 7.01 Regulation FD Disclosure.**

The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.

The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 99.1 | [<u>Press Release dated November 6, 2025 announcing the Company's financial results for the three and nine-month periods ended September 27, 2025</u>](avah-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AVEANNA HEALTHCARE HOLDINGS INC. | AVEANNA HEALTHCARE HOLDINGS INC. |
| Date: November 6, 2025 | By: | /s/ Deborah Stewart |
|  |  | **Deborah Stewart** |
|  |  | **Chief Accounting Officer**<br>**(Principal Accounting Officer)** |

---

------

## Exhibit 99.1

Exhibit 99.1

![img45841609_0.jpg](img45841609_0.jpg)

**AVEANNA HEALTHCARE HOLDINGS ANNOUNCES**

**THIRD QUARTER FINANCIAL RESULTS AND REVISED 2025 OUTLOOK**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•***Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year period***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•***Third Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year period***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•***Adjusted EBITDA for Q3 2025 was $80.1 million, a 67.5% increase over the prior year period***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•***Increased Full Year 2025 Revenue guidance to greater than $2.375 billion, updated from greater than $2.3 billion***

o***Increased Full Year 2025 Adjusted EBITDA guidance to greater than $300 million, updated from greater than $270 million***

**Atlanta, Georgia** (November 6, 2025) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and nine-month periods ended September 27, 2025.

Jeff Shaner, Chief Executive Officer, commented, "Our third quarter results reflect the strength and momentum in all three operating divisions as we continue year three of our Strategic Transformation. The quarter was highlighted by revenue and adjusted EBITDA growth of 22.2% and 67.5%, respectively, when compared to the prior year period. We continue to advocate for our patients and families to receive the value of high-quality health care in the comfort of their home. Our national footprint delivers cost-effective and high-quality home care that provides significant value to our payor and government partners. The integration of Thrive Skilled Pediatric Care is on track to be completed by the end of the year. Our revised guidance demonstrates the sustained momentum we have in our business as we complete 2025. I am proud of our dedicated team of Aveanna caregivers and leaders, who deliver on our mission of exceptional care every day."

*<u>Three-Month Periods Ended September 27, 2025 and September 28, 2024</u>*

Revenue was $621.9 million for the three-month period ended September 27, 2025, as compared to $509.0 million for the three-month period ended September 28, 2024, an increase of $112.9 million, or 22.2%. The overall increase in revenue was attributable to a $104.9 million increase in PDS segment revenue, and a $8.3 million increase in HHH segment revenue, offset by a $0.2 million decrease in MS segment revenue compared to the third quarter of 2024.

Gross margin was $202.8 million, or 32.6% of revenue, for the three-month period ended September 27, 2025, as compared to $159.7 million, or 31.4% of revenue, for the three-month period ended September 28, 2024, an increase of $43.1 million, or 27.0%.

Net income was $14.1 million for the three-month period ended September 27, 2025, as compared to net loss of $42.8 million for the three-month period ended September 28, 2024. Net income per diluted share was $0.06 for the three-month period ended September 27, 2025, as compared to net loss per diluted share of $(0.22) for the three-month period ended September 28, 2024. Adjusted net income per diluted share was $0.15 for the three-month period ended September 27, 2025, as compared to adjusted net income per diluted share of $0.02 for the three-month period ended September 28, 2024. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $80.1 million, or 12.9% of revenue, for the three-month period ended September 27, 2025, as compared to $47.8 million, or 9.4% of revenue, for the three-month period ended September 28, 2024, an increase of $32.3 million or 67.5%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.

------

*<u>Nine-Month Period Ended September 27, 2025 and September 28, 2024</u>*

Revenue was $1,770.7 million for the nine-month period ended September 27, 2025, as compared to $1,504.6 million for the nine-month period ended September 28, 2024, an increase of $266.1 million, or 17.7%. The overall increase in revenue was attributable to a $248.0 million increase in PDS segment revenue, a $15.9 million increase in HHH segment revenue, and a $2.2 million increase in MS segment revenue compared to the first nine months of 2024.

Gross margin was $597.2 million, or 33.7% of revenue, for the nine-month period ended September 27, 2025, as compared to $463.8 million, or 30.8% of revenue, for the nine-month period ended September 28, 2024, an increase of $133.4 million, or 28.8%.

Net income was $46.3 million for the nine-month period ended September 27, 2025, as compared to net loss of $40.1 million for the nine-month period ended September 28, 2024. Net income per diluted share was $0.22 for the nine-month period ended September 27, 2025, as compared to net loss per diluted share of $(0.21) for the nine-month period ended September 28, 2024. Adjusted net income per diluted share was $0.43 for the nine-month period ended September 27, 2025, as compared to adjusted net income per diluted share of $0.01 for the nine-month period ended September 28, 2024. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $235.9 million, or 13.3% of revenue, for the nine-month period ended September 27, 2025, as compared to $128.4 million, or 8.5% of revenue, for the nine-month period ended September 28, 2024, an increase of $107.5 million or 83.7%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.

**Liquidity, Cash Flow, and Debt**

On September 17, 2025, we entered into the fourth joinder and twelfth amendment (the "Refinancing Amendment") to our First Lien Credit Agreement and concurrently terminated our $415.0 million Second Lien Credit Agreement using proceeds from incremental borrowings under the Refinancing Amendment. The Refinancing Amendment expanded our capacity on our revolving credit facility to $250.0 million and extended the maturity dates of our revolving credit facility, as well as our refinanced term loans and an incremental senior secured term loan facility (together, the "2025 Term Loans") to September 17, 2030, and September 17, 2032, respectively. The 2025 Term Loans bear interest at Term SOFR plus 3.75%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As of September 27, 2025, we had cash of $145.9 million and incremental borrowing capacity of $105.8 million under our securitization facility. Our revolver was undrawn, with approximately $227.0 million of borrowing capacity and approximately $23.0 million of outstanding letters of credit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•2025 net cash provided by operating activities was $76.1 million. Free cash flow was $86.2 million for the nine-month period ended September 27, 2025. See "Non-GAAP Financial Measures - Free cash flow" below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•As of September 27, 2025 we had total indebtedness of $1,490.0 million. Our interest rate exposure under our credit facilities is currently hedged with the following instruments:

o$520.0 million notional amount of interest rate swaps that convert variable rate debt to a fixed rate, and

o$880.0 million notional amount of interest rate caps that cap our exposure to SOFR at 2.96%.

Matt Buckhalter, Chief Financial Officer, commented "Our third-quarter results are highlighted by revenue and Adjusted EBITDA growth of 22.2% and 67.5%, respectively, compared to the prior year period. Our team's relentless focus on operational excellence, disciplined execution, and delivering strong clinical outcomes continues to drive our improved results. In addition, our successful debt refinancing completed during the third quarter reflects the strength of our operating performance and proven value of our national home care platform. Based on our performance and the opportunities ahead, we are pleased to raise our full-year 2025 guidance to revenue of greater than $2.375 billion and Adjusted EBITDA of greater than $300 million."

**Full Year 2025 Guidance**

The following is our guidance reflecting our updated expectations for revenue and Adjusted EBITDA for the full fiscal year 2025 (year ending January 3, 2026):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Revenue of greater than $2.375 billion, updated from greater than $2.3 billion

Consistent with prior practice, we are not providing guidance on net income at this time due to the volatility of certain required inputs that are not available without unreasonable efforts, including future fair value adjustments associated with our interest rate swaps and caps.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDA of greater than $300 million, updated from greater than $270 million

**Non-GAAP Financial Measures** 

In addition to our results of operations prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), we also evaluate our financial performance using EBITDA, Adjusted EBITDA, Field contribution, Field contribution margin, Adjusted net income or loss, Adjusted net income or loss per diluted share, and Free cash flow. Given our determination of adjustments in arriving at our computations, these non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to net income or loss, revenue, operating income or loss, cash flows from operating activities, total indebtedness, gross margin, gross margin percentage or any other financial measures calculated in accordance with GAAP. The reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in the financial tables below.

*EBITDA and Adjusted EBITDA* 

EBITDA and Adjusted EBITDA are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as net income or loss. Rather, we present EBITDA and Adjusted EBITDA as supplemental measures of our performance. We define EBITDA as net income or loss before interest expense, net; income tax expense or benefit; and depreciation and amortization. We define Adjusted EBITDA as EBITDA, adjusted for the impact of certain other items that are either non-recurring, infrequent, non-cash, unusual, or items deemed by management to not be indicative of the performance of our core operations, including impairments of goodwill, intangible assets, and other long-lived assets; non-cash, share-based compensation and associated employer payroll taxes; loss on extinguishment of debt; fees related to debt modifications; the effect of interest rate derivatives; acquisition-related and integration costs; legal costs and settlements associated with acquisition matters; restructuring costs; other legal matters; and other system transition costs, professional fees and other costs. As non-GAAP financial measures, our computations of EBITDA and Adjusted EBITDA may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of this measure impracticable.

We believe our computations of EBITDA and Adjusted EBITDA are helpful in highlighting trends in our core operating performance. In determining which adjustments are made to arrive at EBITDA and Adjusted EBITDA, we consider both (1) certain non-recurring, infrequent, non-cash or unusual items, which can vary significantly from year to year, as well as (2) certain other items that may be recurring, frequent, or settled in cash but which we do not believe are indicative of our core operating performance. We use EBITDA and Adjusted EBITDA to assess operating performance and make business decisions.

We have incurred substantial acquisition-related costs and integration costs. The underlying acquisition activities take place over a defined timeframe, have distinct project timelines and are incremental to activities and costs that arise in the ordinary course of our business. Therefore, we believe it is important to exclude these costs from our Adjusted EBITDA because it provides us a normalized view of our core, ongoing operations after integrating our acquired companies, which we believe is an important measure in assessing our performance.

*Field contribution and Field contribution margin*

Field contribution and Field contribution margin are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as gross margin and gross margin percentage. Rather, we present Field contribution and Field contribution margin as supplemental measures of our performance. We define Field contribution as gross margin less branch and regional administrative expenses. Field contribution margin is Field contribution as a percentage of revenue. As non-GAAP financial measures, our computations of Field contribution and Field contribution margin may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of these measures impracticable.

Field contribution and Field contribution margin have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to gross margin, gross margin percentage, net income or loss, revenue, operating income or loss, cash flows from operating activities, total indebtedness or any other financial measures calculated in accordance with GAAP.

Management believes Field contribution and Field contribution margin are helpful in highlighting trends in our core operating performance and evaluating trends in our branch and regional results, which can vary from year to year. We use Field contribution and Field contribution margin to make business decisions and assess the operating performance and results delivered by our core field operations, prior to corporate and other costs not directly related to our field operations. These metrics are also important because they guide us in determining whether or not our branch and regional administrative expenses are appropriately sized to support our caregivers

------

and direct patient care operations. Additionally, Field contribution and Field contribution margin determine how effective we are in managing our field supervisory and administrative costs associated with supporting our provision of services and sale of products.

*Adjusted net income and Adjusted net income per diluted share*

Adjusted net income represents net income (loss) as adjusted for the impact of GAAP income tax, goodwill, intangible and other long-lived asset impairment charges, non-cash share-based compensation expense, loss on extinguishment of debt, fees related to debt modifications; interest rate derivatives, acquisition-related costs, integration costs, legal costs, restructuring costs, other legal matters, other system transition costs, professional fees and certain other miscellaneous items on a pre-tax basis. Adjusted net income includes a provision for income taxes derived utilizing a combined statutory tax rate. The combined statutory tax rate is our estimate of our long-term tax rate. The most comparable GAAP measure is net income (loss).

Adjusted net income per diluted share represents adjusted net income on a per diluted share basis using the weighted-average number of diluted shares outstanding for the period. The most comparable GAAP measure is net income (loss) per share, diluted.

Adjusted net income and adjusted net income per diluted share are important to us because they allow us to assess financial results, exclusive of the items mentioned above that are not operational in nature or comparable to those of our competitors.

*Free cash flow*

Free cash flow is a liquidity measure that represents operating cash flow, adjusted for the impact of purchases of property, equipment and software, proceeds from issuance of term loans, net of debt issuance costs, principal payments on term loans, notes payable and financing leases, and settlements with swap counterparties. The most comparable GAAP measure is cash flow from operations.

We believe free cash flow is helpful in highlighting the cash generated or used by the Company, after taking into consideration mandatory payments on term loans, notes payable and financing leases, as well as cash needed for non-acquisition related capital expenditures, and cash paid to or received from derivative counterparties.

**Conference Call**

Aveanna will host a conference call on Thursday, November 6, 2025, at 10:00 a.m. Eastern Time to discuss our third quarter results. The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A telephonic replay of the conference call will be available until November 13, 2025, by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13755427. A live webcast of our conference call will also be available under the Investor Relations section of our website: <u>https://ir.aveanna.com/</u>. The online replay will also be available for one week following the call.

**Forward-Looking Statements**

Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may," "should," "would," "predict," "project," "potential," "continue," "could," "design," "guidance," or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, such as intense competition among home health, hospice and durable medical equipment companies; our ability to maintain relationships with existing patient referral sources; our ability to have services funded from third-party payers, including Medicare, Medicaid and private health insurance companies, including as a result of changes to Medicaid to be implemented under the One Big Beautiful Bill Act; changes to Medicare or Medicaid rates or methods governing Medicare or Medicaid payments, and the implementation of alternative payment models, including but not limited to Medicare Advantage, Managed Care Organization, managed Medicaid, and other forms of managed care; any downward pressure on reimbursement resulting from further proliferation of Medicare Advantage plans; our limited ability to control reimbursement rates received for our services; delays in collection or non-collection of our patient accounts receivable, particularly during the business integration process, or when transitioning between systems associated with clinical data collection and submission, as well as billing and collection systems; healthcare reform and other regulations, including risks related to the proposed rule issued for the home health prospective payment system by Centers for Medicare & Medicaid Services; changes in the case-mix of our patients, as well as payer mix and payment methodologies; any reduction

------

in net reimbursement if we do not effectively implement value-based care programs; the possibility that our business, financial condition and results of operations may be materially adversely affected by public health emergencies, such as a pandemic or other infectious disease outbreak; shortages in qualified employees and management and competition for qualified personnel; any failure to maintain the security and functionality of our information systems or to defend against or otherwise prevent a cybersecurity attack or breach; our substantial indebtedness, which increases our vulnerability to general adverse economic and industry conditions and may limit our ability to pursue strategic alternatives and react to changes in our business and industry; our ability to identify, obtain financing for, acquire and integrate strategic and accretive businesses or assets; risks related to legal proceedings, claims and governmental inquiries given that the nature of our business exposes us to various liability claims, which may exceed the level of our insurance coverage, and other risks set forth under the heading "Risk Factors" in Aveanna's Annual Report on Form 10-K for its 2024 fiscal year filed with the Securities and Exchange Commission on March 13, 2025, which is available at <u>www.sec.gov</u>. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

**About Aveanna Healthcare**

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 38 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient's normal caregiver. The Company's services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit <u>www.aveanna.com</u>.

------

**Cash Flow and Information about Indebtedness**

The following table sets forth a summary of our cash flows from operating, investing, and financing activities for the periods presented:

---

| | | |
|:---|:---|:---|
|  | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars in thousands)* | **September 27, 2025** | **September 28, 2024** |
| Net cash provided by operating activities | $76137 | $19231 |
| Net cash used in investing activities | $(20349) | $(4790) |
| Net cash provided by financing activities | $5790 | $20079 |
| Cash and cash equivalents at beginning of period | $84288 | $43942 |
| Cash and cash equivalents at end of period | $145866 | $78462 |

---

The following table presents our long-term indebtedness as of September 27, 2025:

---

| | | |
|:---|:---|:---|
| *(dollars in thousands)* |  |  |
| **Instrument** | **Interest Rate** | **September 27, 2025** |
| 2025 Term Loans <sup>(1)</sup> | S + 3.75% | $1325000 |
| 2025 Refinancing Revolving Credit Facility <sup>(1)</sup> | S + 3.75% | - |
| Securitization Facility | S + 2.50% | 165000 |
| Total indebtedness |  | $1490000 |
| <sup>(1)</sup> S = One-month SOFR |  |  |

---

**Results of Operations**

The following table summarizes our consolidated results of operations for the periods indicated (amounts in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
|  | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| Revenue | $621942 | $509023 | $1770719 | $1504634 |
| Cost of revenue, excluding depreciation and amortization | 419118 | 349324 | 1173537 | 1040814 |
| Branch and regional administrative expenses | 95399 | 88184 | 276855 | 264070 |
| Corporate expenses | 52000 | 31894 | 124034 | 91981 |
| Depreciation and amortization | 2599 | 2587 | 7810 | 8332 |
| Acquisition-related costs | (1175) | 150 | 2331 | 150 |
| Other operating expense | 418 | 2860 | 734 | 5271 |
| Operating income | 53583 | 34024 | 185418 | 94016 |
| Interest income | 826 | 100 | 1087 | 297 |
| Interest expense | (35127) | (39245) | (107465) | (118505) |
| Loss on debt extinguishment | (5862) | - | (5862) | - |
| Other (expense) income | (3) | (22211) | (5475) | 2329 |
| Income (loss) before income taxes | 13417 | (27332) | 67703 | (21863) |
| Income tax benefit (expense) | 647 | (15511) | (21421) | (18246) |
| Net income (loss) | $14064 | $(42843) | $46282 | $(40109) |
| Net income (loss) per share: |  |  |  |  |
| Net income (loss) per share, basic | $0.07 | $(0.22) | $0.23 | $(0.21) |
| Weighted average shares of common stock outstanding, basic | 208948 | 193361 | 201529 | 192734 |
| Net income (loss) per share, diluted | $0.06 | $(0.22) | $0.22 | $(0.21) |
| Weighted average shares of common stock outstanding, diluted | 222234 | 193361 | 211920 | 192734 |

---

------

The following tables summarize our consolidated key performance measures, including Field contribution and Field contribution margin, which are non-GAAP measures, for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** |
| *(dollars in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $621942 | $509023 | $112919 | 22.2% |
| Cost of revenue, excluding depreciation and amortization | 419118 | 349324 | 69794 | 20.0% |
| Gross margin | $202824 | $159699 | $43125 | 27.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 32.6% | 31.4% |  | 1.2%<sup>(1)</sup> |
| Branch and regional administrative expenses | 95399 | 88184 | 7215 | 8.2% |
| Field contribution | $107425 | $71515 | $35910 | 50.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Field contribution margin | 17.3% | 14.0% |  |  |
| Corporate expenses | $52000 | $31894 | $20106 | 63.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;As a percentage of revenue | 8.4% | 6.3% |  |  |
| Operating income | $53583 | $34024 | $19559 | 57.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;As a percentage of revenue | 8.6% | 6.7% |  |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $1770719 | $1504634 | $266085 | 17.7% |
| Cost of revenue, excluding depreciation and amortization | 1173537 | 1040814 | 132723 | 12.8% |
| Gross margin | $597182 | $463820 | $133362 | 28.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 33.7% | 30.8% |  | 2.9%<sup>(1)</sup> |
| Branch and regional administrative expenses | 276855 | 264070 | 12785 | 4.8% |
| Field contribution | $320327 | $199750 | $120577 | 60.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Field contribution margin | 18.1% | 13.3% |  |  |
| Corporate expenses | $124034 | $91981 | $32053 | 34.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;As a percentage of revenue | 7.0% | 6.1% |  |  |
| Operating income | $185418 | $94016 | $91402 | 97.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;As a percentage of revenue | 10.5% | 6.2% |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Represents the change in margin percentage year over year (or quarter over quarter).

------

The following tables summarize our key performance measures by segment for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **PDS** | **PDS** | **PDS** | **PDS** |
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** |
| *(dollars and hours in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $514431 | $409558 | $104873 | 25.6% |
| Cost of revenue, excluding depreciation and amortization | 365159 | 299731 | 65428 | 21.8% |
| Gross margin | $149272 | $109827 | $39445 | 35.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 29.0% | 26.8% |  | 2.2%<sup>(4)</sup> |
| Hours | 11822 | 10474 | 1348 | 12.9% |
| Revenue rate | $43.51 | $39.10 | $4.41 | 12.7%<sup>(1)</sup> |
| Cost of revenue rate | $30.89 | $28.62 | $2.27 | 8.9%<sup>(2)</sup> |
| Spread rate | $12.62 | $10.48 | $2.14 | 23.0%<sup>(3)</sup> |
|  | **HHH** | **HHH** | **HHH** | **HHH** |
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** |
| *(dollars and admissions/episodes in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $62427 | $54139 | $8288 | 15.3% |
| Cost of revenue, excluding depreciation and amortization | 29146 | 24948 | 4198 | 16.8% |
| Gross margin | $33281 | $29191 | $4090 | 14.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 53.3% | 53.9% |  | -0.6%<sup>(4)</sup> |
| Home health total admissions <sup>(5)</sup> | 9.7 | 8.9 | 0.8 | 9.0% |
| Home health episodic admissions <sup>(6)</sup> | 7.5 | 6.8 | 0.7 | 10.3% |
| Home health total episodes <sup>(7)</sup> | 12.9 | 11.3 | 1.6 | 14.2% |
| Home health episodic mix <sup>(8)</sup> | 77.3% | 76.4% |  | 0.9%<sup>(10)</sup> |
| Home health revenue per completed episode <sup>(9)</sup> | $3215 | $3104 | $111 | 3.6% |
|  | **MS** | **MS** | **MS** | **MS** |
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** |
| *(dollars and UPS in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $45084 | $45326 | $(242) | -0.5% |
| Cost of revenue, excluding depreciation and amortization | 24813 | 24645 | 168 | 0.7% |
| Gross margin | $20271 | $20681 | $(410) | -2.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 45.0% | 45.6% |  | -0.6%<sup>(4)</sup> |
| Unique patients served ("UPS") | 91 | 92 | (1) | -1.1% |
| Revenue rate | $495.43 | $492.67 | $2.76 | 0.6%<sup>(1)</sup> |
| Cost of revenue rate | $272.67 | $267.88 | $4.79 | 1.8%<sup>(2)</sup> |
| Spread rate | $222.76 | $224.79 | $(2.03) | -0.9%<sup>(3)</sup> |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **PDS** | **PDS** | **PDS** | **PDS** |
|  | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars and hours in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $1460441 | $1212418 | $248023 | 20.5% |
| Cost of revenue, excluding depreciation and amortization | 1018550 | 891588 | 126962 | 14.2% |
| Gross margin | $441891 | $320830 | $121061 | 37.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 30.3% | 26.5% |  | 3.8%<sup>(4)</sup> |
| Hours | 33762 | 31074 | 2688 | 8.7% |
| Revenue rate | $43.26 | $39.02 | $4.24 | 11.8%<sup>(1)</sup> |
| Cost of revenue rate | $30.17 | $28.69 | $1.48 | 5.5%<sup>(2)</sup> |
| Spread rate | $13.09 | $10.33 | $2.76 | 29.0%<sup>(3)</sup> |
|  | **HHH** | **HHH** | **HHH** | **HHH** |
|  | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars and admissions/episodes in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $179272 | $163382 | $15890 | 9.7% |
| Cost of revenue, excluding depreciation and amortization | 82187 | 75814 | 6373 | 8.4% |
| Gross margin | $97085 | $87568 | $9517 | 10.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 54.2% | 53.6% |  | 0.6%<sup>(4)</sup> |
| Home health total admissions <sup>(5)</sup> | 29.2 | 28.4 | 0.8 | 2.8% |
| Home health episodic admissions <sup>(6)</sup> | 22.3 | 21.5 | 0.8 | 3.7% |
| Home health total episodes <sup>(7)</sup> | 37.4 | 35.0 | 2.4 | 6.9% |
| Home health episodic mix <sup>(8)</sup> | 76.4% | 75.7% |  | 0.7%<sup>(10)</sup> |
| Home health revenue per completed episode <sup>(9)</sup> | $3200 | $3089 | $111 | 3.6% |
|  | **MS** | **MS** | **MS** | **MS** |
|  | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars and UPS in thousands)* | **September 27, 2025** | **September 28, 2024** | **Change** | **% Change** |
| Revenue | $131006 | $128834 | $2172 | 1.7% |
| Cost of revenue, excluding depreciation and amortization | 72800 | 73412 | (612) | -0.8% |
| Gross margin | $58206 | $55422 | $2784 | 5.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin percentage | 44.4% | 43.0% |  | 1.4%<sup>(4)</sup> |
| Unique patients served ("UPS") | 271 | 278 | (7) | -2.5% |
| Revenue rate | $483.42 | $463.43 | $19.99 | 4.2%<sup>(1)</sup> |
| Cost of revenue rate | $268.63 | $264.07 | $4.56 | 1.7%<sup>(2)</sup> |
| Spread rate | $214.79 | $199.36 | $15.43 | 7.5%<sup>(3)</sup> |

---

1)Represents the period over period change in revenue rate, plus the change in revenue rate attributable to the change in volume.

2)Represents the period over period change in cost of revenue rate, plus the change in cost of revenue rate attributable to the change in volume.

3)Represents the period over period change in spread rate, plus the change in spread rate attributable to the change in volume.

4)Represents the change in margin percentage year over year (or quarter over quarter).

5)Represents home health episodic and other admissions.

6)Represents home health episodic admissions.

7)Represents episodic admissions and recertifications.

8)Represents the ratio of home health episodic admissions to home health total admissions.

9)Represents Medicare revenue per completed episode.

10)Represents the change in home health episodic mix year over year (or quarter over quarter).

------

The following table reconciles gross margin and gross margin percentage to Field contribution and Field contribution margin:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars in thousands)* | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| Gross margin | $202824 | $159699 | $597182 | $463820 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Gross margin percentage* | 32.6% | 31.4% | 33.7% | 30.8% |
| Branch and regional administrative expenses | 95399 | 88184 | 276855 | 264070 |
| Field contribution | $107425 | $71515 | $320327 | $199750 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Field contribution margin* | 17.3% | 14.0% | 18.1% | 13.3% |
| Revenue | $621942 | $509023 | $1770719 | $1504634 |

---

The following table reconciles net income (loss) to EBITDA and Adjusted EBITDA:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars in thousands)* | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| Net income (loss) | $14064 | $(42843) | $46282 | $(40109) |
| Interest expense, net | 34301 | 39145 | 106378 | 118208 |
| Income tax (benefit) expense | (647) | 15511 | 21421 | 18246 |
| Depreciation and amortization | 2599 | 2587 | 7810 | 8332 |
| EBITDA | 50317 | 14400 | 181891 | 104677 |
| Goodwill, intangible and other long-lived asset impairment | 418 | 2904 | 738 | 5304 |
| Non-cash share-based compensation | 4960 | 4902 | 21115 | 12483 |
| Loss on debt extinguishment | 5862 | - | 5862 | - |
| Fees related to debt modifications | 15964 | - | 15964 | - |
| Interest rate derivatives <sup>(1)</sup> | 9 | 22141 | 5532 | (2218) |
| Acquisition-related costs <sup>(2)</sup> | (1175) | 150 | 2332 | 150 |
| Integration costs <sup>(3)</sup> | 2250 | 262 | 4793 | 949 |
| Legal costs and settlements associated with acquisition matters <sup>(4)</sup> | 1550 | 848 | 3228 | 1423 |
| Restructuring <sup>(5)</sup> | 52 | 1599 | 468 | 4787 |
| Other legal matters <sup>(6)</sup> | 12 | 214 | (5926) | 1112 |
| Other adjustments <sup>(7)</sup> | (91) | 421 | (141) | (296) |
| Total adjustments | $29811 | $33441 | $53965 | $23694 |
| Adjusted EBITDA | $80128 | $47841 | $235856 | $128371 |

---

The following table reconciles net income (loss) to adjusted net income and presents adjusted net income per diluted share:

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars in thousands, except share and per share data)* | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| Net income (loss) | $14064 | $(42843) | $46282 | $(40109) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense | (647) | 15511 | 21421 | 18246 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill, intangible and other long-lived asset impairment | 418 | 2904 | 738 | 5304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash share-based compensation | 4960 | 4902 | 21115 | 12483 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | 5862 | - | 5862 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Fees related to debt modifications | 15964 | - | 15964 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate derivatives <sup>(1)</sup> | 9 | 22141 | 5532 | (2218) |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related costs <sup>(2)</sup> | (1175) | 150 | 2332 | 150 |
| &nbsp;&nbsp;&nbsp;&nbsp;Integration costs <sup>(3)</sup> | 2250 | 262 | 4793 | 949 |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal costs and settlements associated with acquisition matters <sup>(4)</sup> | 1550 | 848 | 3228 | 1423 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring <sup>(5)</sup> | 52 | 1599 | 468 | 4787 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other legal matters <sup>(6)</sup> | 12 | 214 | (5926) | 1112 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other adjustments <sup>(7)</sup> | (91) | 421 | (141) | (296) |
| Total adjustments | 29164 | 48952 | 75386 | 41940 |
| Adjusted pre-tax income | 43228 | 6109 | 121668 | 1831 |
| Income tax expense on adjusted pre-tax income <sup>(8)</sup> | (10807) | (1527) | (30417) | (458) |
| Adjusted net income | $32421 | $4582 | $91251 | $1373 |
| Weighted average shares outstanding, diluted <sup>(9)</sup> | 222234 | 200984 | 211920 | 197844 |
| Adjusted net income per diluted share <sup>(10)</sup> | $0.15 | $0.02 | $0.43 | $0.01 |

---

The following footnotes are applicable to tables above that reconcile (i) net income (loss) to EBITDA and Adjusted EBITDA and (ii) net income (loss) to adjusted net income.

(1)Represents valuation adjustments and settlements associated with interest rate derivatives that are not included in interest expense, net. Such items are included in other (expense) income.

(2)Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, and finance and accounting diligence and documentation, as presented on the Company's consolidated statements of operations.

(3)Represents (i) costs associated with our Integration Management Office, which focuses on our integration efforts and transformational projects such as systems conversions and implementations, material cost reduction and restructuring projects, among other things, of $0.5 million and $1.2 million for the three and nine-month periods ended September 27, 2025, respectively, and $0.3 million and $0.8 million for the three and nine-month periods ended September 28, 2024, respectively; and (ii) transitionary costs incurred to integrate acquired companies into our field and corporate operations of $1.8 million and $3.6 million for the three and nine-month periods ended September 27, 2025, respectively, and $0.1 million for the nine-month period ended September 28, 2024. No such cost was recorded during the three-month period ended September 28, 2024. Transitionary costs incurred to integrate acquired companies include IT consulting costs and related integration support costs; salary, severance and retention costs associated with duplicative acquired company personnel until such personnel are exited from the Company; accounting, legal and consulting costs; expenses and impairments related to the closure and consolidation of overlapping markets of acquired companies, including lease termination and relocation costs; costs associated with terminating legacy acquired company contracts and systems; and one-time costs associated with rebranding our acquired companies and locations to the Aveanna brand.

(4)Represents legal and forensic costs, as well as settlements associated with resolving legal matters arising during or as a result of our acquisition-related activities. This primarily includes (i) costs of $1.3 million and $2.6 million for the three and nine-month periods ended September 27, 2025, respectively, and $0.4 million and $1.0 million for the three and nine-month periods ended September 28, 2024, respectively, to comply with the U.S. Department of Justice, Antitrust Division's grand jury subpoena related to nurse wages and hiring activities in certain of our markets, in connection with a terminated transaction.

(5)Represents costs associated with restructuring our branch and regional administrative footprint as well as our corporate overhead infrastructure costs in order to appropriately size our resources to current volumes, including: (i) branch and regional salary and severance costs; (ii) corporate salary and severance costs; and (iii) rent and lease termination costs associated with the closure of certain office locations.

------

(6)Represents activity related to accrued legal settlements and the related costs and expenses associated with certain judgments and arbitration awards rendered against the Company where certain insurance coverage is in dispute. The Company released a legal reserve related to a certain accrued legal settlement during the nine-month period ended September 27, 2025.

(7)Represents: (i) other costs or (income) that are either non-cash or non-core to the Company's ongoing operations of $(0.1) million and $(0.1) million for the three and nine-month periods ended September 27, 2025, respectively, and $0.4 million and $(0.3) million for the three and nine-month periods ended September 28, 2024, respectively.

(8)Derived utilizing a combined federal and state statutory rate of 25% for the three and nine-month periods ended September 27, 2025, and September 28, 2024, respectively, and applied to the respective adjusted pre-tax income.

(9)Weighted average shares outstanding, diluted for the three and nine-month periods ended September 28, 2024 include 7.6 million and 5.1 million additional dilutive shares, respectively, that are not presented within our consolidated results of operations due to net loss for the three and nine-month periods ended September 28, 2024, as their inclusion in calculating net loss per share would be antidilutive. The dilutive shares are included within the calculation of adjusted net income per dilutive share for the three and nine-month periods ended September 28, 2024 above, as their effect would have been dilutive.

(10)Adjustments used to reconcile net income (loss) per diluted share on a GAAP basis to adjusted net income per diluted share are comprised of the same adjustments, inclusive of the tax impact, used to reconcile net income (loss) to adjusted net income divided by the weighted-average diluted shares outstanding during the period.

The following table reconciles net income (loss) to adjusted net income and presents adjusted net income per diluted share:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** | **For the three-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
|  | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** | **September 27, 2025** | **September 27, 2025** | **September 28, 2024** | **September 28, 2024** |
| *(dollars in thousands)* | **Dollars** | **Per Diluted Share** | **Dollars** | **Per Diluted Share** | **Dollars** | **Per Diluted Share** | **Dollars** | **Per Diluted Share** |
| Net income (loss) | $14064 | $0.06 | $(42843) | $(0.21) | $46282 | $0.22 | $(40109) | $(0.20) |
| Total adjustments <sup>(1)</sup> | 29164 | 0.14 | 48952 | 0.24 | 75386 | 0.36 | 41940 | 0.21 |
| Income tax expense benefit on adjusted pre-tax income | (10807) | (0.05) | (1527) | (0.01) | (30417) | (0.15) | (458) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (0.00) |
| Adjusted net income | $32421 | $0.15 | $4582 | $0.02 | $91251 | $0.43 | $1373 | $0.01 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Total adjustments agree to the net income (loss) to adjusted net income table above.

The table below reflects the increase or decrease, and aggregate impact, to the line items included on our consolidated statements of operations based upon the adjustments used in arriving at Adjusted EBITDA from EBITDA for the periods indicated.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three-month periods ended** | **For the three-month periods ended** | **For the nine-month periods ended** | **For the nine-month periods ended** |
| *(dollars in thousands)* | **September 27, 2025** | **September 28, 2024** | **September 27, 2025** | **September 28, 2024** |
| Cost of revenue, excluding depreciation and amortization | $353 | $281 | $(5225) | $457 |
| Branch and regional administrative expenses | 2003 | 2515 | 6841 | 5389 |
| Corporate expenses | 22346 | 5421 | 37945 | 14756 |
| Acquisition-related costs | (1175) | 150 | 2331 | 150 |
| Other operating expense | (12) | (8) | 34 | 2112 |
| Loss on debt extinguishment | 5862 | - | 5862 | - |
| Other expense (income) | 434 | 25082 | 6177 | 830 |
| Total adjustments | $29811 | $33441 | $53965 | $23694 |

---

The following table reconciles the net cash used in operating activities to free cash flow:

------

---

| | |
|:---|:---|
|  | **For the nine-month period ended** |
| *(dollars in thousands)* | **September 27, 2025** |
| Net cash provided by operations | $76137 |
| Purchases of property and equipment, and software | (5496) |
| Proceeds from issuance of term loans, net of debt issuance costs | 1317743 |
| Principal payments of term loans | (1305550) |
| Principal payments of notes payable and financing lease obligations | (5854) |
| Settlements with swap counterparties | 9170 |
| Free cash flow | $86150 |

---

------